… oral ganciclovir diminished the incidence of CMV disease but, as evidenced in this study,
did not completely eliminate the risk for developing CMV disease, especially among CMV D + /…

… By administering intravenous ganciclovir during the course … of CMV disease is brought back
to baseline; if oral ganciclovir is … of the intravenous therapy, essentially all CMV disease is …

… in the CMV DNA level after the initiation of intravenous ganciclovir treatment. … CMV DNA
levels in PBMC at the time of CMV disease diagnosis that declined after intravenous ganciclovir …

… Whereas almost all CMV-seropositive recipients will develop CMV … CMV disease, primarily
CMV pneumonia (5,11) . Although treatment of established CMV disease with ganciclovir …

… We compared the effects of oral valganciclovir with those of intravenous ganciclovir as
induction therapy for newly diagnosed cytomegalovirus retinitis in 160 patients with the acquired …

… Accordingly, our results indicate that pre-emptive use of CMVIG is highly effective in
preventing CMV disease in CMV-seropositive transplant recipients. The absence of CMV disease …

… The standard induction treatment of gastrointestinal CMV disease uses intravenous ganciclovir,
though the use of oral valganciclovir is increasing, especially for long-term maintenance …

… reconstitution against CMV. Delayed … ) CMV disease after HSCT in this era of preemptive
therapy. Foscarnet and valganciclovir are the available alternatives to intravenous ganciclovir. …

… CMV disease in nine SOT recipients. … Cytomegalovirus infection was defined as a positive
CMV-specific assay in the absence of clinical symptoms, and CMV disease as a positive CMV …

… -term sequelae of CMV (12). Despite the use of combination therapy with IV ganciclovir and
CMV-IGIV, we also saw a significant incidence of BOS after CMV, albeit somewhat delayed …